The recognition of these peptide–MHC complexes by CD8+ CTLs triggers their activation, leading to the expansion of tumour‐specific CTLs capable of targeting and eliminating cancer cells expressing TAAs (Figure 3).58 The gene discussed is CD8A; the disease is neoplasm.